Searchable abstracts of presentations at key conferences in endocrinology

ea0077p3 | Adrenal and Cardiovascular | SFEBES2021

Improving outcomes from SSTS: Redefining Cortisol Cut-Offs

Choudhury Sirazum , Ramadoss Vijay , Lazarus Katharine , Tan Tricia , Meeran Karim

Background: Short Synacthen Tests (SSTs) are integral to the diagnosis of Adrenal Insufficiency (AI). A 30-minute stimulated cortisol value is assessed against local assay dependent thresholds to ascertain or exclude the diagnosis. A diagnosis of AI is a life changing event requiring the initiation of life long glucocorticoid replacement therapy for survival. Glucocorticoid replacement is associated with long term morbidity and mortality, including an increased risk of diabete...

ea0077p19 | Adrenal and Cardiovascular | SFEBES2021

Prednisolone versus Hydrocortisone in Adrenal Insufficiency: A positive and negative control cross-sectional study

Choudhury Sirazum , Lazarus Katharine , Thaventhiran Thilipan , Tan Tricia , Meeran Karim

Background: Management of adrenal insufficiency (AI) with glucocorticoid replacement is associated with increased mortality and morbidity. There is growing evidence that this is because of excess, non-physiological steroid exposure. Low dose prednisolone (2-4 mg) is a once-daily alternative to standard hydrocortisone regimens that more closely mimics the circadian rhythm and may translate to better outcomes. There is however a paucity of studies comparing the two treatments.</...

ea0077p151 | Adrenal and Cardiovascular | SFEBES2021

Iatrogenic Cushing’s syndrome due to betamethasone nasal drops

Alameri Majid , Alnuaimi Abdulla , Patel Kalpesh , Meeran Karim , Wernig Florian

Introduction: Iatrogenic Cushing’s syndrome (ICS) can be caused by virtually all forms of steroid treatment with or without suppression of hypothalamic–pituitary–adrenal (HPA) axis. Here we report betamethasone nasal drops used as treatment post septorhinoplasty as a cause of iatrogenic Cushing’s syndrome.Case: A 36 years old female with background history of depression presented to endocrinology clinic for evaluation of progressive w...

ea0081p530 | Adrenal and Cardiovascular Endocrinology | ECE2022

Objective markers and new indicators in adrenal insufficiency- findings from the omni-aid study comparing hydrocortisone and prednisolone replacement therapy

Choudhury Sirazum , Thaventhiran Thilipan , Lazarus Katharine , Tan Tricia , Meeran Karim

Background: Adrenal insufficiency (AI) is a life-threatening condition if left unmanaged. Despite treatment patients can expect a life expectancy that is shortened by 12 years secondary to probable inherent over-replacement associated with oral glucocorticoid regimens. Thrice-daily hydrocortisone is the most common regimen used. Very low-dose prednisolone (2-4 mg) is an alternative with lower uptake due to the absence of evidence for its use. This study fills this literature g...

ea0081ep716 | Pituitary and Neuroendocrinology | ECE2022

Pituitary Hyperplasia secondary to Severe Primary Hypothyroidism

Esdaile Harriet , Alameri Majid , Alnuaimi Abdulla , Martin Niamh , Meeran Karim

Introduction: Thyrotroph pituitary hyperplasia in context of severe primary hypothyroidism is rare and usually occurs due to loss of thyroxine feedback inhibition and overproduction of thyrotropin-releasing hormone, leading to pituitary gland enlargement. Pituitary hyperplasia caused by primary hypothyroidism responds well to thyroid hormone replacement therapy and rarely requires surgical intervention. Case presentation: A 42-year-old female with backgr...

ea0050p015 | Adrenal and Steroids | SFEBES2017

How relevant is aldosterone and cortisol co-secretion?

Bhatt Padmanabh Shrikant , Sam Amir H , Salem Victoria , Meeran Karim

Background: Studies suggest that glucocorticoid hypersecretion alongside primary hyperaldosteronism (PA) is common and may contribute to the adverse metabolic phenotype. Adrenal crisis post-surgery for PA is rare.Aim: To determine the prevalence of cortisol co-secretion in PA in patients at Imperial College London NHS Trust, Hammersmith Hospital (a tertiary referral centre for adrenal tumours).Methods: Am...

ea0050p018 | Adrenal and Steroids | SFEBES2017

Prednisolone should be first line replacement therapy for adrenal insufficiency

Prabhudev Hemanth , Smith David , Choudhury Sirazum , Meeran Karim

Introduction: We offer patients needing glucocorticoid replacement in primary and secondary adrenal insufficiency the choice of either once daily prednisolone or thrice daily hydrocortisone. A recent European study found no difference between prednisolone and hydrocortisone users in several markers, including glucose, weight, body mass index (BMI), systolic and diastolic blood pressure and waist circumference, although they did suggest an increase in cholesterol and low densit...

ea0050p015 | Adrenal and Steroids | SFEBES2017

How relevant is aldosterone and cortisol co-secretion?

Bhatt Padmanabh Shrikant , Sam Amir H , Salem Victoria , Meeran Karim

Background: Studies suggest that glucocorticoid hypersecretion alongside primary hyperaldosteronism (PA) is common and may contribute to the adverse metabolic phenotype. Adrenal crisis post-surgery for PA is rare.Aim: To determine the prevalence of cortisol co-secretion in PA in patients at Imperial College London NHS Trust, Hammersmith Hospital (a tertiary referral centre for adrenal tumours).Methods: Am...

ea0050p018 | Adrenal and Steroids | SFEBES2017

Prednisolone should be first line replacement therapy for adrenal insufficiency

Prabhudev Hemanth , Smith David , Choudhury Sirazum , Meeran Karim

Introduction: We offer patients needing glucocorticoid replacement in primary and secondary adrenal insufficiency the choice of either once daily prednisolone or thrice daily hydrocortisone. A recent European study found no difference between prednisolone and hydrocortisone users in several markers, including glucose, weight, body mass index (BMI), systolic and diastolic blood pressure and waist circumference, although they did suggest an increase in cholesterol and low densit...

ea0086p161 | Adrenal and Cardiovascular | SFEBES2022

Prednisolone replacement therapy in Adrenal Insufficiency: Defining target ranges and timing for optimum Prednisolone level sampling

Sharma Angelica , Lazarus Katharine , Choudhury Sirazum , Meeran Karim

Introduction: Glucocorticoid replacement in adrenal insufficiency may be achieved by administering thrice- daily hydrocortisone or once-daily very low dose (2-4 mg) prednisolone. Prednisolone’s longer half-life enables once-daily dosing, improving patient satisfaction and compliance. At very low doses, it has shown no difference in most markers of metabolic risk when compared with hydrocortisone. At Imperial College Healthcare NHS Trust (ICHNT), use of an eight-hour troug...